- Home
- INCR vs ANVS Comparison
INCR vs ANVS Comparison
Compare INCR & ANVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INCR | ANVS |
|---|---|---|
| Founded | 1994 | 2008 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 58.6M | 50.4M |
| IPO Year | 2021 | 2019 |
Fundamental Metrics
Financial Performance| Metric | INCR | ANVS |
|---|---|---|
| Price | $5.01 | $1.05 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $10.50 |
| AVG Volume (30 Days) | 3.5K | ★ 779.2K |
| Earning Date | 10-27-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 39.39 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $200.38 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.68 | $1.04 |
| 52 Week High | $6.10 | $5.50 |
Technical Indicators
Market Signals| Indicator | INCR | ANVS |
|---|---|---|
| Relative Strength Index (RSI) | 48.39 | 33.55 |
| Support Level | $0.81 | $1.04 |
| Resistance Level | $5.58 | $1.43 |
| Average True Range (ATR) | 0.18 | 0.08 |
| MACD | -0.14 | 0.00 |
| Stochastic Oscillator | 19.51 | 2.63 |
Price Performance
Historical ComparisonAbout INCR Intercure Ltd.
Intercure Ltd is engaged in the research, cultivation, production, and distribution of pharma-grade cannabis-based products. Its products are available in dried inflorescences or liquid oil form, and are marketed through various brands, including Pharmo Cann, Humboldt, Indoor, Space Labs, Canndoc Utopia, Binske, Canndoc Stars, and others. The company has two operating segments, namely Investments in portfolio companies in the biomed sector and Investments in the medical cannabis sector. A majority of its revenue is generated from the Cannabis segment.
About ANVS Annovis Bio Inc.
Annovis Bio Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's flagship candidate, buntanetap, is in clinical trials for the treatment of Alzheimer's disease, Parkinson's disease, and Lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia.